CCL4抗体—艾普蒂

+ +

•  

   

     Black line: Control Antigen (100 ng);Purple line: Antigen (10ng); Blue line: Antigen (50 ng); Red line:Antigen (100 ng)    

  
  

•  

   

     Flow cytometric analysis of HL-60 cells using CCL4 mouse mAb (green) and negative control (red).    

  
  

The C-C motif chemokine ligand 4 (CCL4), also known as macrophage inflammatory protein-1β (MIP-1β), is a small cytokine involved in immune regulation and inflammatory responses. It binds to chemokine receptors CCR5 and CCR8. recruiting immune cells like monocytes, dendritic cells, and T-lymphocytes to sites of infection or injury. CCL4 plays roles in host defense, autoimmune diseases, and cancer progression, and is notable for its interaction with HIV-1. as it competes with the virus for CCR5 binding.

CCL4 antibodies are immunodetection tools or therapeutic candidates targeting this chemokine. As research reagents, monoclonal or polyclonal CCL4 antibodies enable the quantification and localization of CCL4 in tissues or biofluids via techniques like ELISA, Western blot, or immunohistochemistry. These antibodies help study CCL4's role in diseases such as rheumatoid arthritis, HIV infection, and tumor microenvironments, where its overexpression correlates with immune cell infiltration and disease severity.

Therapeutically, anti-CCL4 antibodies are explored for modulating pathological inflammation or blocking viral entry in HIV. By neutralizing CCL4. they may suppress excessive immune cell recruitment in autoimmune conditions or disrupt CCR5-mediated HIV infection pathways. Challenges include ensuring specificity and minimizing off-target effects, given the overlapping functions of chemokines. Current research focuses on optimizing antibody affinity and evaluating efficacy in preclinical models, positioning CCL4 antibodies as potential tools for both diagnostic and therapeutic innovation.